Ledraxen (Enoxaparin Sodium)

• Ledraxen is a low molecular weight heparin used to manage and prevent venous thromboembolism.
• Prevention of deep vein thrombosis (DVT) in surgical patients: reduces clot formation after orthopedic or abdominal surgery.
• Treatment of acute deep vein thrombosis: promotes clot resolution and prevents propagation.
• Prevention and treatment of pulmonary embolism: limits embolic events in at‑risk patients.
• Anticoagulation in acute coronary syndrome: decreases recurrent ischemic events.
• Anticoagulation during hemodialysis: maintains circuit patency while minimizing bleeding.

• Enoxaparin Sodium binds to antithrombin III, enhancing its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This accelerated inhibition disrupts the conversion of prothrombin to thrombin and fibrin formation, thereby reducing clot development without markedly affecting platelet function.

Enoxaparin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Injection site reactions: erythema, pain, or bruising at the injection site.
• Minor bleeding: epistaxis, gum bleeding, or easy bruising.
• Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Major hemorrhage: life‑threatening internal bleeding.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop.
• Allergic reactions: anaphylaxis, urticaria, or angioedema.
• Spinal/epidural hematoma: bleeding in the spinal canal after neuraxial procedures.

• When prescribing Ledraxen, clinicians should consider several safety precautions to minimize risk.
• Renal impairment: adjust dose or avoid in severe renal failure.
• Bleeding risk: avoid in patients with active bleeding or recent major surgery.
• Concomitant anticoagulants: monitor closely when used with warfarin, antiplatelet agents, or thrombolytics.
• Pregnancy: use only if benefit outweighs risk (Category B).
• Elderly patients: monitor for accumulation and bleeding.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Enoxaparin can interact with other medicines, altering its anticoagulant effect.

Major Interactions (Avoid)

• Concurrent use with full‑dose warfarin: increased risk of severe bleeding.
• Combination with direct thrombin inhibitors (e.g., dabigatran): additive anticoagulation.
• Use with systemic thrombolytics (e.g., alteplase): heightened hemorrhagic risk.
• Co‑administration with high‑dose NSAIDs: potentiates bleeding.
• Concurrent spinal/epidural anesthesia with enoxaparin: risk of spinal hematoma.

Moderate Interactions (Monitor Closely)

• Low‑dose aspirin: may increase minor bleeding.
• SSRIs: modest increase in bleeding tendency.
• Heparin flushes during catheter use: additive anticoagulant effect.
• Antibiotics affecting gut flora (e.g., ciprofloxacin): possible alteration of platelet function.
• Vitamin K antagonists: monitor INR closely.